April 16, 2025 | Boston
From June 23rd to 27, Swissnex will host 10 Swiss startups in Boston as part of Venture Leaders Biotech 2025. During the weeklong program, the members of the “Swiss National Startup Team” will exchange with key investors, business leaders, and experts in the area’s life sciences sector.
Throughout the week, the Venture Leaders will explore the world’s leading life sciences hub, pitching to investors and VCs, learning about the specifics of the US business environment from entrepreneurs with extensive experience in the Boston ecosystem, and making connections that can facilitate market entry.
The Venture Leaders Biotech 2025 are:
- Abrinca | A powerful tool for genome data management and comparative genomics, delivering maximum insights from well-organized data and speeding up the R&D process
- Amporin Pharmaceuticals | Developing a breakthrough new class of therapies for the treatment of neurodegenerative diseases associated with protein misfolding and aggregation
- Apricot Therapeutics | Creating the “Google Maps” of the tumor cell by combining drug perturbations, image-based phenotypic profiling, systems biology approaches, and robust predictive modelling.
- Aukera Therapeutics | Leveraging AI-driven protein design to drive drug discovery on complex targets, with a focus on developing a first-in-class, fully selective mTORC1 inhibitor for rare neurological disorders and cancers
- ENANTIOS | Instrumentation and services for the characterization of chiral molecules, accelerate drug development and discovery and enable more complete quality testing in the manufacturing stage
- Encelta | Offering a groundbreaking allogeneic T-cell product with the potential to make cell therapy accessible and affordable for patients with blood cancers, solid tumors, and autoimmune diseases
- HemostOD | A unique & scalable platelet manufacturing platform that enables the generation of large quantities of homogeneous and high-quality platelets in a few hours
- InkVivo Technologies | Fabricating drug delivery systems with a precise spatial composition and formulation to regulate the release of the encapsulated ingredients over time.
- Juvion Life Sciences | Developing advanced therapeutics to preserve neuron-muscle connectivity, address immobility and sarcopenia, and extend healthspan.
- Nerai Bioscience | Unlocking the full potential of genetic medicines using highly personalized CRISPR proteins to deliver lifelong cures for diseases beyond the reach of current genome editing.
Members of previous Venture Leaders Biotech cohorts have achieved significant success. In 2023, Alentis, a participant in the fall 2022 roadshow, closed a $105 million Series C funding round with participation by RA Capital Management, a Boston-based multi-stage investment manager focused on healthcare and life sciences. Also in 2023, Bionomous, another participant in the fall 2022 roadshow, closed a $2.7 million Series A funding round with participation by Cybernetix Ventures, a Boston-based venture capital firm focused on robotics. Earlier this year, BioVersys, a participant in the 2008 roadshow, went public on the SIX Swiss Exchange with a CHF 213 million IPO.
Venture Leaders Biotech is organized by Venturelab in partnership with Swissnex in Boston and supported by the University of Basel, EPFL, ETH Zurich, Hansjörg Wyss, Kellerhals Carrard, and VISCHER.